Mankind Pharma, which recently made its stock exchange debut, has been added to several Nifty indices, including Nifty500 and Nifty Midcap150. The decision reflects the Indian pharmaceutical firm's position as the fourth largest in the domestic space and the third largest by sales volume. The company currently enjoys a solid marketing presence and runs 25 manufacturing facilities across India. Mankind's shares rose nearly 29% above their listed price, closing at INR1,675 ($22.7) on Tuesday. Meanwhile, Kotak Institutional Equities reportedly has a buy recommendation on the stock with a target price of INR1,875. Coveted index Nifty will also see a couple of changes, with LTI Mindtree replacing HDFC and Zydus Lifesciences taking over from Jindal Steel & Power in Nifty Midcap Select.